Skip to main content

Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.

Publication ,  Journal Article
Gandorfer, A; Benz, MS; Haller, JA; Stalmans, P; Pakola, SJ; Girach, A; Kampik, A; Toth, CA; Jaffe, GJ; MIVI-TRUST Study Group,
Published in: Retina
June 2015

PURPOSE: To evaluate visual function in patients with symptomatic vitreomacular adhesion (VMA)/vitreomacular traction including when associated with macular hole after ocriplasmin treatment, and the association between resolution of the underlying condition and improvement in visual function. METHODS: Six hundred and fifty-two patients from 2 Phase 3 trials received a single intravitreal injection of ocriplasmin 125 μg (n = 464) or placebo (n = 188). Mean and categorical changes from baseline in best-corrected visual acuity and 25-item Visual Function Questionnaire scores were used to evaluate visual function. Subgroups with VMA resolution and full-thickness macular hole closure were compared. RESULTS: Overall, 42% of patients who achieved VMA resolution at Day 28 had a ≥2-line improvement in best-corrected visual acuity at Month 6, and 20% had a ≥3-line improvement. Likewise, 69% of patients with nonsurgical full-thickness macular hole closure at Day 28 had a ≥2-line improvement at Month 6, and 48% had a ≥3-line best-corrected visual acuity improvement. Mean improvements in 25-item Visual Function Questionnaire scores were associated with achieving VMA resolution and nonsurgical full-thickness macular hole closure. CONCLUSION: In patients with symptomatic VMA/vitreomacular traction, VMA resolution and nonsurgical full-thickness macular hole closure were each associated with improvements in visual function. Resolving the underlying anatomical condition in symptomatic VMA/vitreomacular traction will increase the probability of achieving a clinically meaningful improvement in visual function.

Duke Scholars

Published In

Retina

DOI

EISSN

1539-2864

Publication Date

June 2015

Volume

35

Issue

6

Start / End Page

1151 / 1157

Location

United States

Related Subject Headings

  • Vitreous Body
  • Visual Acuity
  • Tissue Adhesions
  • Surveys and Questionnaires
  • Sickness Impact Profile
  • Retinal Perforations
  • Retinal Diseases
  • Peptide Fragments
  • Ophthalmology & Optometry
  • Intravitreal Injections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gandorfer, A., Benz, M. S., Haller, J. A., Stalmans, P., Pakola, S. J., Girach, A., … MIVI-TRUST Study Group, . (2015). Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Retina, 35(6), 1151–1157. https://doi.org/10.1097/IAE.0000000000000508
Gandorfer, Arnd, Matthew S. Benz, Julia A. Haller, Peter Stalmans, Stephen J. Pakola, Aniz Girach, Anselm Kampik, Cynthia A. Toth, Glenn J. Jaffe, and Glenn J. MIVI-TRUST Study Group. “Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.Retina 35, no. 6 (June 2015): 1151–57. https://doi.org/10.1097/IAE.0000000000000508.
Gandorfer A, Benz MS, Haller JA, Stalmans P, Pakola SJ, Girach A, Kampik A, Toth CA, Jaffe GJ, MIVI-TRUST Study Group. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole. Retina. 2015 Jun;35(6):1151–1157.

Published In

Retina

DOI

EISSN

1539-2864

Publication Date

June 2015

Volume

35

Issue

6

Start / End Page

1151 / 1157

Location

United States

Related Subject Headings

  • Vitreous Body
  • Visual Acuity
  • Tissue Adhesions
  • Surveys and Questionnaires
  • Sickness Impact Profile
  • Retinal Perforations
  • Retinal Diseases
  • Peptide Fragments
  • Ophthalmology & Optometry
  • Intravitreal Injections